An official website of the United States government
Home
Name
ATRA-IV
Alternate Names
Vesanoid
Abbreviations
None
Category
Differentiation inducing agent
Subcategory
Retinoid: please see Remarks for coding instructions
NSC Number
None
Primary Site
Lymphoma
Acute promyelocytic leukemia
Histology
None
Remarks
Atra is currently in clinical trials for Head & Necks cancers. It is under investigation as treatment of Kaposi Sarcoma. DO NOT CODE ATRA has treatment for these sites/histologies until FDA approval. Code as either 2, 3, or 6 in Other Therapy field.
ATRA has received FDA approval for treatment of Acute Promyelocytic Leukemia (APL). ATRA should be coded "1" in Other Therapy field.
Liposomal all-trans retinoic acid. Antigenics, Inc.
ATRA has received FDA approval for treatment of Acute Promyelocytic Leukemia (APL). ATRA should be coded "1" in Other Therapy field.
Liposomal all-trans retinoic acid. Antigenics, Inc.
Coding
This drug should be coded
